Landmark Novelties, Inc. v. Arkansas State Board of Pharmacy

2010 Ark. 40, 358 S.W.3d 890, 2010 Ark. LEXIS 53
CourtSupreme Court of Arkansas
DecidedJanuary 28, 2010
DocketNo. 08-543
StatusPublished
Cited by12 cases

This text of 2010 Ark. 40 (Landmark Novelties, Inc. v. Arkansas State Board of Pharmacy) is published on Counsel Stack Legal Research, covering Supreme Court of Arkansas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Landmark Novelties, Inc. v. Arkansas State Board of Pharmacy, 2010 Ark. 40, 358 S.W.3d 890, 2010 Ark. LEXIS 53 (Ark. 2010).

Opinion

DONALD L. CORBIN, Justice.

Appellant Landmark Novelties, Inc., appeals from an order of the Pulaski County Circuit Court affirming a decision of Appellee Arkansas State Board of Pharmacy to suspend Landmark’s license to sell List 1 chemicals for a period of three years and to impose a $175,000 civil penalty. These penalties were a consequence of the board’s findings that Landmark had violated Ark.Code Ann. § 5-64-1006 (Repl. 2005) and the board’s regulation 08-02 by failing to report suspicious transactions involving List 1 chemicals and by storing List 1 chemicals in an unlicensed and inappropriately equipped facility. For reversal, Landmark contends that it was denied due process because section 5-64-1006 and its supporting regulations are impermissi-bly vague as applied and that the board’s decision was arbitrary, capricious, and not supported by substantial evidence. This appeal requires interpretation of the Arkansas Constitution; therefore, our jurisdiction is pursuant to Ark. Sup.Ct. R. 1-2(a)(1) and (b) (2009). We find that neither argument for reversal has merit and affirm the circuit court’s order.

I. Regulatory Framework

Landmark describes itself as a foreign corporation with its principal place of business in Quincy, Illinois, engaged in the business of merchandising specialty items such as greeting cards, work gloves, driving maps, cigarette lighters, energy pills, and over-the-counter medications to convenience stores and other retail outlets in thirteen states. Landmark is licensed by the board as a wholesale distributor of List 1 chemicals and is consequently required by statute to report suspicious orders of certain List 1 chemicals to the board. Ark.Code Ann. § 5-64-1006(a).

Pseudo ephedrine, in addition to having a legitimate use as an active ingredient in over-the-counter allergy and cold medications, is also a List 1 chemical that the board found to be in great demand as an ingredient used in the illicit manufacture of methamphetamine, a controlled substance. In an attempt to protect the citizens of Arkansas from the harmful effects of methamphetamine abuse and from exposure to illicit laboratories used for the manufacture of methamphetamine, the General Assembly enacted legislation requiring the sale of pseudoephedrine, ephedrine, and other List 1 chemicals in a suspicious transaction to be reported in writing to the board. Ark.Code Ann. § 5-64-1006. Section 5-64-1006(c)(l) defines a reportable “suspicious transaction” as one whose circumstances would lead a reasonable person to believe that the substance is likely to be used for the purpose of unlawfully manufacturing a controlled substance based on four factors: the amount involved, the method of payment, the method of delivery, and past dealings with the person acquiring the substance. Ark. Code Ann. § 5-64-1006(c)(l)(A)-(D). In addition, section 5-64-1006(c)(2) establishes a clear rule that cash or money order transactions of more than $200 are “suspicious transactions.”

In addition to setting out a statutory definition of “suspicious transaction,” section 5-64-1006(d)(l) directs the board to adopt criteria for determining whether a transaction is suspicious. In response, the board promulgated regulation 08-02-0008. 070-00-008 Ark.Code R. 08-02-0008 (Weil 2009). Thus, in addition to the four statutory factors enumerated in section 5-64-1006(c)(1), regulation 08-02-0008 sets forth twenty-five additional factors for its licensees to consider in determining whether, in “their best judgment,” a transaction is suspicious. Among others, those twenty-five factors include such things as customers who do not seem to know industry practice or who fail to provide reasons for an order at variance with accepted legitimate industry practice; a new customer who does not seem to know federal or state government regulations; customers who want predominantly or only regulated chemicals; customers who want multiple regulated or surveillance list products, particularly if in contrast to customary use and practice; a customer who is vague or resists providing information about the firm’s address, telephone number, and reason for seeking that chemical; an established customer who deviates from pi-evious orders or ordering methods; and a customer who requests unusual methods of delivery or routes of shipment or who provides unusual shipping, labeling, or packaging instructions.

Finally, with respect to the regulatory framework that Landmark challenges on this appeal, we note that the failure to comply with the reporting requirements of section 5-64-1006 is a Class A misdemean- or, and that the board is authorized to impose a civil penalty not to exceed $10,000 per violation. Ark.Code Ann. § 5-64 — 1006(b), (d)(2).

II. Procedural History

The board’s action in this case began with an investigation into whether Landmark was properly reporting suspicious orders of pseudoephedrine pursuant to section 5-64-1006 and regulation 08-02-0008. The board issued a written order with findings of fact and conclusions of law on September 10, 2004.

In its written order, the board found that specifically, single-ingredient 60 mg pseudoephedrine is highly desired in the illicit manufacturing of methamphetamine and that Landmark sold primarily Max Brand 60 mg single-ingredient pseu-doephedrine to its customers, which included primarily convenience stores and some truck stops, but also other types of “non-traditional” outlets that do not generally sell over-the-counter pharmaceutical products. The board found that Landmark failed to report any of its sales of pseudoephedrine to the board as a suspicious order. The board further found that for over two years during 2001 through 2003, Landmark maintained a storage facility for List 1 chemicals without a license and without the proper alarm system and temperature and humidity controls.

Based on these findings of fact, the board concluded Landmark had violated section 5-64-1006, regulation 08-02-0002(a), regulation 08-02-0006(b), regulation 08-02-0006(c), and regulation 08-02-0008(a)(8), by failing to report suspicious orders of pseudoephedrine and by maintaining an unlicensed and improperly maintained storage facility for List 1 chemicals. As previously stated, the board suspended Landmark’s license for a three-year period, and ordered a civil penalty of $175,000 to be paid at the conclusion of the suspension.

Landmark, pursuant to the Arkansas Administrative Procedure Act (AAPA), specifically Ark.Code Ann. § 25-15-212 (Repl.2002), filed a petition for review in circuit court, arguing (1) that the board’s application of the statute and regulation violated its rights of due process under article 2, section 8 of the Arkansas Constitution, and (2) that the board’s decision was arbitrary, capricious, and not supported by substantial evidence. After a hearing on the petition, the circuit court affirmed the board, holding that its decision was supported by substantial evidence and was not arbitrary or capricious. Furthermore, the circuit court concluded that the board’s enforcement of the statute and regulation satisfied due process under article 2, section 8. This appeal followed.1

III. Due Process — Vagueness as Applied

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Arkansas Blue Cross and Blue Shield v. Freeway Surgery Center
2024 Ark. App. 540 (Court of Appeals of Arkansas, 2024)
Arkansas Ethics Commission v. Susan K. Weaver
2021 Ark. 38 (Supreme Court of Arkansas, 2021)
Ozark Mountain Reg'l Pub. Water Auth. v. Arkansas Attorney General
2020 Ark. App. 180 (Court of Appeals of Arkansas, 2020)
W.N. v. Ark. Dep't of Human Servs.
552 S.W.3d 483 (Court of Appeals of Arkansas, 2018)
3 Rivers Logistics, Inc. v. Brown-Wright Post No. 158 of the Am. Legion
548 S.W.3d 137 (Supreme Court of Arkansas, 2018)
Steffy v. City of Fort Smith
545 S.W.3d 804 (Court of Appeals of Arkansas, 2018)
Abraham v. Beck
2015 Ark. 80 (Supreme Court of Arkansas, 2015)
Capstone Oilfield Disposal of Arkansas, Inc. v. Pope County
408 S.W.3d 65 (Court of Appeals of Arkansas, 2012)
Opinion No.
Arkansas Attorney General Reports, 2010
Smith v. Arkansas Midstream Gas Services Corp.
2010 Ark. 256 (Supreme Court of Arkansas, 2010)
Linder v. Arkansas Midstream Gas Services Corp.
2010 Ark. 117 (Supreme Court of Arkansas, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
2010 Ark. 40, 358 S.W.3d 890, 2010 Ark. LEXIS 53, Counsel Stack Legal Research, https://law.counselstack.com/opinion/landmark-novelties-inc-v-arkansas-state-board-of-pharmacy-ark-2010.